75% of autistic children stayed on CBD-rich cannabis treatment for 6 months with substantial reported benefits
Among 87 autistic children receiving CBD-rich cannabis, 75% adhered to the 6-month treatment with relatively mild side effects and substantial parent-reported benefits, though some families struggled with dosing regimens and unrealistic expectations.
Quick Facts
What This Study Found
75% adherence rate over 6 months. Side effects were relatively mild. Parents reported substantial benefits for children and families. Barriers included the complex intake regime, some side effects, and in certain cases unrealistic parental expectations about treatment outcomes.
Key Numbers
87 autistic children. 75% adherence rate at 6 months. CBD-rich cannabis preparation. Relatively mild side effects. Barriers: intake regime, side effects, unrealistic expectations.
How They Did This
Explanatory sequential mixed-methods study of 87 autistic children and their families receiving 6-month CBD-rich cannabis treatment. Quantitative analysis of characteristics and adherence combined with qualitative parent interviews about benefits and barriers.
Why This Research Matters
Medical cannabis for autism is growing in use but adherence data are scarce. A 75% adherence rate is relatively high for a 6-month treatment in children, suggesting that when properly supported, families can maintain cannabis-based interventions for autism.
The Bigger Picture
As more families explore cannabis for autism, understanding what supports treatment success becomes critical. This study identifies specific, addressable factors that can improve adherence, from simplifying dosing to setting realistic expectations.
What This Study Doesn't Tell Us
No control group or randomization. Parent-reported benefits may be biased by expectations. Single-center study. CBD-rich products vary, limiting generalizability to other formulations. 6-month timeframe may not reflect longer-term adherence.
Questions This Raises
- ?Would longer follow-up show maintained or declining adherence?
- ?Which specific autism symptoms responded best to CBD-rich cannabis?
- ?How do adherence rates compare to conventional autism treatments?
Trust & Context
- Key Stat:
- 75% adherence rate over 6 months
- Evidence Grade:
- Mixed-methods study with reasonable sample size. Limited by lack of control group, parent-reported outcomes, and single-center design.
- Study Age:
- Published in 2024 in Medical Cannabis and Cannabinoids.
- Original Title:
- Characteristics for Medical Cannabis Treatment Adherence among Autistic Children and Their Families: A Mixed-Methods Analysis.
- Published In:
- Medical cannabis and cannabinoids, 7(1), 68-79 (2024)
- Authors:
- David, Ayelet(3), Stolar, Orit(6), Berkovitch, Matitiahu(7), Kohn, Elkana, Waisman-Nitzan, Michal, Hartmann, Inbar, Gal, Eynat
- Database ID:
- RTHC-05251
Evidence Hierarchy
Frequently Asked Questions
Do families stick with cannabis treatment for autism?
In this study, 75% of families maintained treatment over 6 months, which is relatively high. Those who dropped out often struggled with the dosing routine, side effects, or had expectations that did not match outcomes.
Were there significant side effects?
Side effects were described as relatively mild. The study noted that while some side effects contributed to dropout, the treatment was generally well-tolerated. The main barriers were practical (dosing regime) rather than safety-related.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-05251APA
David, Ayelet; Stolar, Orit; Berkovitch, Matitiahu; Kohn, Elkana; Waisman-Nitzan, Michal; Hartmann, Inbar; Gal, Eynat. (2024). Characteristics for Medical Cannabis Treatment Adherence among Autistic Children and Their Families: A Mixed-Methods Analysis.. Medical cannabis and cannabinoids, 7(1), 68-79. https://doi.org/10.1159/000538901
MLA
David, Ayelet, et al. "Characteristics for Medical Cannabis Treatment Adherence among Autistic Children and Their Families: A Mixed-Methods Analysis.." Medical cannabis and cannabinoids, 2024. https://doi.org/10.1159/000538901
RethinkTHC
RethinkTHC Research Database. "Characteristics for Medical Cannabis Treatment Adherence amo..." RTHC-05251. Retrieved from https://rethinkthc.com/research/david-2024-characteristics-for-medical-cannabis
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.